- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Trishan Panch Outlines the Larger Care Coordination Problem
The medication adherence problem is emblematic of the larger coordinated care issue in the US healthcare system, according to Trishan Panch, MBBS, MPH, chief medical officer at Wellframe.
While medication adherence seems, at the surface, like a fairly simple thing to do, there are barriers that prevent the patients who most need those medication from taking them, Trishan Panch, MBBS, MPH, chief medical officer at Wellframe, said at the Patient-Centered Diabetes Care meeting, co-hosted by The American Journal of Managed Care and Joslin Diabetes Center, April 16-17 in Boston.
He added that the medication adherence problem is emblematic of the larger coordinated care issue in the US healthcare system.
"We believe that you have to not just coordinate medication, you've got to coordinate visits, you've got to learn about the condition, you've got to test the understanding of that learning, screen for secondary complications of the condition, and manage risk factors underlying the specific disease," he explained.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
